

**GLYCOGEN SYNTHASE KINASE-3 β (GSK-3 β)
INHIBITORS FROM SOIL ACTINOMYCETES OF
SABAH RAINFORESTS: SCREENING,
PURIFICATION AND IDENTIFICATION**



FAUZE BIN MAHMUD

UMS
UNIVERSITI MALAYSIA SABAH

**FACULTY OF SCIENCE AND NATURAL RESOURCES
UNIVERSITI MALAYSIA SABAH
2015**

**GLYCOGEN SYNTHASE KINASE-3 β (GSK-3 β)
INHIBITORS FROM SOIL ACTINOMYCETES OF
SABAH RAINFORESTS: SCREENING,
PURIFICATION AND IDENTIFICATION**

FAUZE BIN MAHMUD



UMS

**THIS IS SUBMITTED IN PARTIAL
FULFILLMENT FOR THE DEGREE OF MASTER
OF SCIENCE**


**FACULTY OF SCIENCE AND NATURAL RESOURCES
UNIVERSITI MALAYSIA SABAH
2015**

DECLARATION

I hereby declare that the material in this thesis is my own except for quotations, excerpts, equations, summaries and references, which have been duly acknowledged.

31 August 2014

Fauze Bin Mahmud
PS20108219



UMS
UNIVERSITI MALAYSIA SABAH

CERTIFICATION

NAME : **FAUZE BIN MAHMUD**
MATRIC. NO : **PS20108219**
TITLE : **GLYCOGEN SYNTHASE KINASE-3 β (GSK-3 β)
INHIBITORS FROM SOIL ACTINOMYCETES OF SABAH
RAINFORESTS: SCREENING, PURIFICATION AND
IDENTIFICATION**
DEGREE : **MASTER OF SCIENCE (BIOTECHNOLOGY)**
VIVA DATE : **13 APRIL 2015**

CERTIFIED BY

1. MAIN SUPERVISOR

Assoc. Prof. Dr. Lee Ping Chin

Signature



UMS
UNIVERSITI MALAYSIA SABAH

ACKNOWLEDGEMENT

Alhamdulillah, all praises towards the Almighty Allah S.W.T., with all of His consent and blessing, I finally managed to finish my research and thesis writing.

First and foremost, I would like to express my deepest gratitude to my supervisor, Associate Professor Dr. Lee Ping Chin, for her exceptional scientific suggestions, advice and support during the course of finishing my research and thesis-writing. My appreciation also goes to Associate Professor Dr. How Siew Eng and Associate Professor Dr. Jualang Azlan Gansau for their useful advices to enhance the quality of my research and thesis. Appreciation also to Professor Dato Dr. Mohammed Noor Embi, Dr. Hasidah Mohd. Sidek and Dr. Jalifah Latip from UKM for their support. Sincere thanks to MOSTI and SLAB for the grant and scholarship awards.

I would like to thank all my current and previous lab members in UMS especially to Dayang Nurazierah Fachyuni Abd. Aziz, Mohd. Aizuddin Mohd. Bukhari and Norhaniza Johansah for their ideas, suggestions and support which really helped me go through hard times in the laboratory. Not forgotten to my former lab colleagues, Hong Chia Yean, Ch'ng Ai Ying, Khoo Yau Liang, Nurul Ain Ismail, Azlinah Matawali, Ainil Farhan Udayappan, Jury Taunson Tise, Sivakamy Sunitharam and Saima Masood for sharing their valuable knowledge.

Special thanks for my loving parents, Mahmud Bin Hussin and Masra Binti Nimung, for raising me, giving me continuous love, prayers, motivation, encouragement and financial support. Appreciation also to my supportive siblings who always encourage me to pursue my dream. Last but not least, I sincerely thank Mr. Oike Atsushi and his family, for the friendship and for always being there during my good or worst time throughout these years. Without the love, support and encouragement from my family and friends, it would have been impossible for me to finish my study. To all of you, I dedicate this thesis.

Fauze Mahmud
31 August 2014

ABSTRACT

Glycogen Synthase Kinase-3 (GSK-3) is a multitasking enzyme involved in various processes cell. It is expressed in two isoforms in mammalian cells; GSK-3 α and GSK-3 β . Dysregulation of GSK-3 is a causal factor of diseases such as cancer and diabetes. In drug discovery, GSK-3 β is usually being targeted as its activity is more understood compared with GSK-3 α . Small molecule originated from nature is regarded as the best inhibitor for GSK-3 β that be used for treatment due to their novel structural features and potent activity. Actinomycetes are recognized as prolific producers of active compounds, including potent GSK-3 β inhibitor such as staurosporine and manzamine A. External factors such as nutrient availability and pH may influence the production of secondary metabolites by actinomycetes. GSK-3 β inhibitors were previously identified in *Streptomyces* sp. isolated from primary rainforests of Sabah. Due to unexplored potential of actinomycetes from Sabah rainforests, the possibility of finding more inhibitors from actinomycetes of Sabah is promising. In this study, 640 strains of actinomycetes were isolated from 156 soil sample of different forest types in Sabah. Kruskal-Wallis analysis revealed that a large number of isolated strains from secondary forest in which significantly related to the soil pH. Slightly acidic soils were found to yield more strains compared with alkaline soils. Based on the preliminary screening using a yeast-based assay of 505 strains, 14 positive strains were identified. Three strains (FA013, FH025 and H11809) were chosen to be partitioned using LLE. Of the three, H11809 was chosen to be further fractionated using column chromatography due to consistent and potential inhibitory activity. Fractionation of H11809 chloroform extract yielded two active fractions; F4 and F8, in which F8 showed no toxic activity against yeast. Further analysis of F8 using FTIR revealed that carbonyl ester as the major functional group. It was supported by GCMS in which carbonyl ester is the functional group of major compound; dibutyl phthalates (SI >90 %). Carbonyl group was reported to facilitate the binding of numerous inhibitors with GSK-3 β . Minor compound; cyclo-leu-pro (SI >80 %), was also chosen to be further studied due to the presence of carbonyl group as well (carbonyl amide). Identification was supported by spiking using commercially-purchased pure compounds. Both compounds were shown to inhibit the activity of GSK-3 β based on a yeast-based and kinase assays. Michaelis-Menten and Lineweaver-Burke plots showed that dibutyl phthalates inhibited GSK-3 β with mixed inhibition and cyclo-leu-pro uncompetitive inhibition. IC₅₀ values of dibutyl phthalates indicated active (IC₅₀ =3.1 μ M) inhibitory activity against GSK-3 β while cyclo-leu-pro exhibited moderate inhibition (IC₅₀ =12.94 μ M). In conclusion, GSK-3 β inhibitors were successfully identified from actinomycetes strain H11809, and may serve as a good lead to be further developed since non-ATP competitive inhibitors are the main interests in drug discovery.

ABSTRAK

PERENCAT GLIKOGEN SINTASE KINASE-3 β (GSK-3 β) DARIPADA AKTINOMISET TANAH HUTAN HUJAN SABAH: PENYARINGAN, PENULENAN DAN PENGENALPASTIAN

Glikogen sintase kinase-3 (GSK-3 β) merupakan enzim pelbagai fungsi yang terlibat dalam banyak proses sel. Ia diekspresikan dalam dua isoforms di dalam sel mamalia; GSK-3 α and GSK-3 β . Gangguan pada regulasi GSK-3 merupakan punca kepada kanser dan diabetes. Dalam proses penemuan ubat-ubatan, GSK-3 β sering disasarkan kerana aktiviti yang lebih difahami berbanding GSK-3 α . Molekul kecil daripada sumber semulajadi dianggap sebagai perencat yang baik kerana struktur kimianya yang unik dan aktiviti yang kuat. Aktinomiset merupakan pengeluar sebatian kimia yang banyak, termasuklah perencat GSK-3 β seperti staurosporine dan manzamine A. Faktor luaran seperti nutrisi dan pH boleh mempengaruhi metabolit sekunder yang dihasilkan oleh aktinomiset. Sebelum ini, perencat GSK-3 β telah dikenal pasti daripada *Streptomyces* sp. yang diisolasi daripada hutan hujan primer Sabah. Memandangkan aktinomiset di hutan hujan Sabah kurang dikaji, kemungkinan untuk menjumpai lebih banyak perencat adalah tinggi. Dalam kajian ini, 640 strain aktinomiset telah diisolasi daripada 156 tanah daripada pelbagai jenis hutan di Sabah. Analisa Kruskal-Wallis menunjukkan bahawa, bilangan strain yang kebanyakannya diisolasi daripada hutan sekunder dipengaruhi oleh pH tanah. Tanah yang sedikit berasid didapati menghasilkan lebih banyak strain berbanding tanah alkali. Saringan awal terhadap 505 strain menggunakan esei berasaskan yis, dan 14 strain aktif telah dikenal pasti. Tiga strain (FA013, FH025 dan H11809) telah dipilih untuk pemisahan menggunakan teknik LLE. H11809 telah dipilih daripada tiga strain untuk proses fraksinasi menggunakan kromatografi turus kerana aktiviti perencat yang konsisten dan berpotensi. Fraksinasi ekstrak kloroform H11809 menghasilkan dua fraksi aktif; F4 dan F8, dimana F8 tidak menunjukkan aktiviti toksik kepada yeast. Analisa selanjutnya keatas F8 menggunakan FTIR menunjukkan bahawa karbonil ester merupakan kumpulan berfungsi utama. Ianya disokong melalui GCMS dimana karbonil ester adalah kumpulan berfungsi dibutil phthalate (SI >90 %). Kumpulan karbonil dilaporkan membantu perlekatan pelbagai perencat kepada GSK-3 β . Sebatian minor (cyclo-leu-pro (SI >80 %)) juga dipilih untuk kajian selanjutnya kerana kewujudan kumpulan karbonil (karbonil amid). Pengenalpastian disokong dengan spiking menggunakan sebatian komersial tulen yang dibeli. Kedua-dua sebatian merencat aktiviti GSK-3 β berdasarkan esei berasaskan yis dan kinase. Plot Michaelis-Menten and Lineweaver-Burke menunjukkan dibutil phthalate merencat GSK-3 β dengan rencatan campuran dan cyclo-leu-pro rencatan tidak kompetitif. Nilai IC_{50} dibutil phthalate ($IC_{50} = 3.1 \mu M$) menunjukkan rencatan aktif terhadap GSK-3 β , manakala cyclo-leu-pro mempunyai rencatan sederhana ($IC_{50} = 12.94 \mu M$). Kesimpulannya, perencat GSK-3 β telah berjaya dikenal pasti daripada strain aktinomiset H11809, dan berpotensi untuk menjadi calon ubatan yang baik untuk dikembangkan kerana perencat yang tidak bersaing dengan ATP adalah sasaran utama dalam penemuan ubat-ubatan.

LIST OF CONTENTS


	Page
TITLE	i
DECLARATION	ii
CERTIFICATION	iii
ACKNOWLEDGEMENT	iv
ABSTRACT	v
ABSTRAK	vi
LIST OF CONTENTS	vii
LIST OF TABLES	xii
LIST OF FIGURES	xiv
LIST OF ABBREVIATIONS	xix
LIST OF SYMBOLS	xxi
LIST OF APPENDICES	xxii
CHAPTER 1: INTRODUCTION	1
1.1 Introduction	1
1.2 Objectives of the study	3
1.3 Scope of the study	4
CHAPTER 2: LITERATURE REVIEW	5
2.1 Glycogen synthase kinase-3 (GSK-3)	5
2.1.1 Background and structure of GSK-3	5
2.1.2 The importance of GSK-3	8
a. Wnt signaling	9
b. Determining cell survival and death	10
c. Association of GSK-3 with microtubules	13
2.1.3 Diseases associated with GSK-3 and its potential as a therapeutic target	15
a. Alzheimer's disease	16
b. Cancer	18
2.2 General properties of GSK-3 inhibitors and their binding sites	19
2.3 Types of GSK-3 inhibitor and its mechanisms	21
2.3.1 ATP-competitive inhibitors	21
a. General properties of ATP-competitive inhibitor	21
b. Mechanisms of ATP-competitive inhibitor	23
2.3.2 Non ATP-competitive inhibitor	27
2.3.3 Uncompetitive inhibitor	30
2.4 <i>In vivo</i> assay to screen for GSK-3 β inhibitor	31
2.4.1 The pros and cons of various model organisms	32
2.4.2 A Yeast-based system to screen for GSK-3 β inhibitor	34
2.5 <i>In vitro</i> kinase assay to evaluate the activity of GSK-3 β inhibitor	36

2.5.1	The pros and cons of various <i>in vitro</i> assays	36
2.5.2	Kinase-Glo™ luminescence kinase assay to validate the activity of active compound(s) against human recombinant GSK-3β <i>in vitro</i>	38
2.6	Nature as a reservoir for GSK-3 inhibitor	39
2.6.1	Actinomycetes	42
	a. Characteristics	42
	b. Actinomycetes as producers of bioactive compounds	42
2.6.2	Known GSK-3 inhibitor from actinomycetes and their undiscovered potentials	43
2.6.3	GSK-3 inhibitors isolated from actinomycetes of Sabah rainforests	46
CHAPTER 3: ISOLATION OF SOIL ACTINOMYCETES FROM SABAH RAINFORESTS AND STATISTICAL ANALYSIS ON THE FACTORS THAT INFLUENCE SOIL PREVALENCE		48
3.1	Introduction	48
3.2	Methods	50
3.2.1	Isolation of actinomycetes	50
3.2.2	Pure culture and morphological observation of the isolates	51
3.2.3	Strain preservations	51
3.2.4	Statistical analysis	51
	a. Isolates prevalence based on sampling locations	51
	b. Kruskal-Wallis analysis	52
3.3	Results and Discussion	52
3.3.1	Soil sample collection and isolation of actinomycetes	52
3.3.2	Pure culture and morphological characterization of isolated strains	58
3.3.3	Statistical analysis to determine the effect of forest types on total number of yield strains	60
	a. Isolate prevalence based on forest types	60
	b. Kruskal-Wallis analysis	61
3.3.4	Statistical analysis on the effect of soil pH on total yield of isolates	63
3.4	Summary	64
CHAPTER 4: SCREENING FOR GSK-3β INHIBITORS USING A YEAST-BASED SYSTEM		65
4.1	Introduction	65
4.2	Methods	67
4.2.1	Cultivation and extraction of secondary metabolites from actinomycetes	67

4.2.2	Screening for GSK-3 β inhibitors using a yeast-based screening system	67
4.2.3	Subsequent test for the preliminary evaluation on the specificity of the inhibitors towards GSK-3 β using a yeast-based system	68
	a. Screening for MAPK kinase (MKK1) inhibitors	68
	b. Screening for MAPK Phosphatase (MSG5) inhibitors	69
	c. Screening for PP1 inhibitors	69
4.2.4	Liquid-liquid extraction	70
4.3	Results and Discussion	71
4.3.1	Screening for GSK-3 β inhibitors using a yeast-based system	71
4.3.2	Factors affecting the production of secondary metabolites from actinomycetes isolated from secondary forests	74
4.3.3	The preliminary evaluation on the activity of the active acetone crude extracts against other kinase and phosphatase proteins	75
4.3.4	Further separation of the selected active crude extract using liquid-liquid extraction (LLE)	76
4.4	Summary	80
	CHAPTER 5: OPTIMIZATION OF H11809 GROWTH AND MASS SECONDARY METABOLITES PRODUCTION	82
5.1	Introduction	82
5.2	Methods	84
5.2.1	Optimization of H11809 growth and secondary metabolites extraction	84
	a. Carbon source	84
	b. Extraction of intracellular and extracellular secondary metabolites	84
5.2.2	Study of growth curve	85
5.3	Results and Discussion	86
5.3.1	Determination of suitable carbon source for optimum secondary metabolites production	86
5.3.2	Effect of intracellular and extracellular extraction on the inhibitory activity of H11809	87
5.3.3	Growth curve of H11809	89
5.4	Summary	92
	CHAPTER 6: FRACTIONATION AND IDENTIFICATION OF ACTIVE COMPOUNDS FROM H11809	93
6.1	Introduction	93
6.2	Methods	95
6.2.1	Sample preparation	95
6.2.2	Thin layer chromatography (TLC)	95
6.2.3	Column chromatography	95

6.2.4	Profiling of the active fractions using high performance liquid chromatography (HPLC)	96
6.2.5	The analysis of F8 using FTIR	96
6.2.6	Compounds identifications using gas chromatography-mass spectrometry (GC-MS)	96
6.2.7	Confirmation of the identified compound by spiking the GC-MS peaks using commercially-purchased pure compounds	97
6.3	Results and Discussion	98
6.3.1	Development of mobile system using thin layer chromatography	98
6.3.2	Fractionation of H11809 (chloroform layer) and the inhibitory activity of collected fractions against mammalian GSK-3 β	101
6.3.3	Further analysis on the selected fractions	104
	a. Thin layer chromatography analysis of F4, F7 and F8	104
	b. Profiling of F4 and F8 using HPLC	106
6.3.4	Further analysis on F8 using FTIR	108
6.3.5	Compound identification from F8 using GC-MS	108
6.3.6	Selection of compound(s) to be further studied	109
	a. Analysis on MF and RMF	109
	b. Analysis based on structural features	110
	c. Reported biological activities of cyclo-leu-pro and dibutyl phthalates	111
6.3.7	Confirmation of the identified compounds by spiking the peaks using pure compounds	113
6.4	Summary	114
CHAPTER 7: DETERMINATION OF CYCLO-LEU-PRO AND DIBUTYL PHTHALATES ACTIVITIES AGAINST GSK-3β AND ITS INHIBITORY MECHANISMS USING A YEAST-BASED AND <i>IN VITRO</i> KINASE ASSAY		115
7.1	Introduction	115
7.2	Methods	116
7.2.1	Sample preparation	116
7.2.2	A yeast-based system to evaluate the activity of cyclo-leu-pro and dibutyl phthalates	116
7.2.3	<i>In vitro</i> assay using kinase glo™ luminescence enzymatic assay	116
	a. Reagents	117
	b. GSK-3 β assay protocol	117
	c. Determination of inhibitory activities and mechanisms exerted by cyclo-leu-pro and dibutyl phthalates against GSK-3 β	118
	d. IC ₅₀ determination	119
7.3	Results and Discussion	120
7.3.1	Inhibitory activity of commercially-purchased pure compounds against mammalian GSK-3 β tested using	120

	a yeast-based assay	
7.3.2	<i>In vitro</i> activity of cyclo-leu-pro and dibutyl phthalates	121
7.3.3	Determination of inhibitory mechanisms exerted tested compounds based on changes of K_m and V_{max} values	122
	a. Inhibitory mechanisms exerted by cyclo-leu-pro	124
	b. Inhibitory mechanisms exerted by dibutyl phthalates	128
7.3.4	Determination of IC_{50} values	132
	a. IC_{50} value of cyclo-leu-pro	132
	b. IC_{50} value of dibutyl phthalates	133
7.3.5	The implication of inhibitory mechanisms exerted by cyclo-leu-pro and dibutyl phthalates	133
7.4	Summary	135
CHAPTER 8: CONCLUSIONS		137
REFERENCES		139
APPENDIX		173



UMS
UNIVERSITI MALAYSIA SABAH

LIST OF TABLES

		Page
Table 2.1	The glycogen synthase kinase (GSK) nomenclature introduced by Cohen (1982) for possible kinase proteins responsible for the regulation of glycogen synthase (shown below in bold)	5
Table 2.2	The structure of staurosporine isolated from <i>Streptomyces staurosporeus</i> and the modified compounds	45
Table 3.1	The list codes and pH of soils obtained from different sampling locations	54
Table 3.2	Total number of isolated strains from different sampling sites	58
Table 3.3	Morphological characterization of some selected isolates	59
Table 3.4	Soil prevalence that is categorized into four groups based on its sampling locations	60
Table 3.5	Multiple comparisons of sampling location types based on mean differences using Kruskal-Wallis analysis	61
Table 3.6	Multiple comparisons of soils pH based on mean differences using Kruskal-Wallis analysis	63
Table 4.1	Total number of isolated and screened strains from respective sampling locations	72
Table 4.2	Strains that produce active compounds that inhibit GSK-3 β and strains with toxic effect towards the cell	74
Table 4.3	Anti-kinases (GSK-3 β , MKK1 and MSG5) and anti-phosphatase (PP1) activity of actinomycetes crude extracts isolated from primary and secondary forests	76
Table 4.4	The activity of acetone crude extracts of the selected strains to be further partitioned using LLE. The each strain was cultured in triplicates and incubated under same condition for 5 days	77
Table 4.5	The inhibitory activity of dried extracts obtained from LLE of H1809, FA013 and FH025 against GSK-3 β at 100 mg/mL (20 μ L/discs)	79

Table 5.1	The details of sample preparation to study the activity of intra- and extracellular metabolites of H11809	85
Table 5.2	The activity of H11809 with different types of carbon source	86
Table 5.3	The activity of H11809 with varies treatment against GSK-3 β , tested at 2 mg/disc	88
Table 5.4	Screening using crude extract obtained from the mass production of H11809, sampled and tested for every 24 hours	89
Table 5.5	Optical density of H11809 broth culture for 10 days at constant temperature of 28 °C and 150 rpm. Maximum ZOI was observed on the 8 th days (in red) of cultivation for secondary metabolites	90
Table 6.1	The structural comparison of identified compounds from GC-MS and commercial pure compounds for spiking	98
Table 6.2	The bands of compounds observed on TLC at 365 nm, separated using different mobile system	100
Table 6.3	The pooling of fractions collected from column chromatography	101
Table 6.4	Results of screening using pooled fractions of H11809 (from column chromatography)	103
Table 6.5	The TLC profile of F4 and F8 in comparison with the chloroform extract of H11809 prior to column chromatography	105
Table 6.6	Further analysis of F4 and F8 using modified mobile system applied	106
Table 6.7	The MF and RMF values of the identified compounds in reference to NIST11 library	110
Table 7.1	The interpretation of inhibitory mechanisms based on the changes of K_m and V_{max} values	119
Table 7.2	The activity of cyclo-leu-pro and dibutyl phthalates tested using a yeast-based system	120

LIST OF FIGURES

		Page
Figure 2.1	Genes that are expressing GSK-3 α (Chr 3) and GSK-3 β (Chr 19)	6
Figure 2.2	Simplified schematic representation of human GSK-3 α and GSK-3 β	7
Figure 2.3	The binding sites of the primed substrate (F67 and 89-95 loop), phosphate group from primed substrate (P-binding pocket) and pseudo-substrate (D181) on GSK-3 β	8
Figure 2.4	In the absence of Wnt, GSK-3 β will form a protein complex with axin, APC and GSK-3 β substrate, β -catenin. The substrate is then phosphorylated and leads to its degradation. In response to Wnt, the GSK-3 β is not phosphorylated and the substrate needs to be in un-phosphorylated state as well. GSK-3 β binds with GBP/Frat and Dvl. The un-phosphorylated β -catenin is then accumulated in the nucleus and initiates the transcription of LEF/TCF	10
Figure 2.5	The involvement of GSK-3 β with apoptosis in neurons cells. The activation of GSK-3 β will inhibit the activity of β -catenin and CREB and prevents the binding with CBP. Free CBP binds with another transcription factor, p53 which promote apoptosis	12
Figure 2.6	GSK-3 β regulates the binding of various structural proteins such as tau, MAP1B and kinesin to microtubules. Phosphorylation of MAP1B, kinesin and APC increases their affinity towards the microtubule. Conversely, phosphorylation of Tau prevents its binding	15
Figure 2.7	Un-phosphorylated Tau is able to bind with microtubule (a). The hyper-phosphorylation of Tau by GSK-3 β will prevent Tau to bind (b). The unbound Tau is forming the Tau filament/tangles, which is the classic characteristic of Alzheimer disease (c)	16
Figure 2.8	The association of GSK-3 β with Alzheimer's disease. High activity of GSK-3 will cause the formation of plaques and tangles due to high phosphorylation of A β and Tau. Conversely, the activity of transcription factors decreases due to phosphorylation by GSK-3 β that leads to cell death	17

Figure 2.9	The potential of GSK-3 β inhibitor to cure neurodegenerative disease. High activity of GSK-3 β will causes inhibition of transcription factor activation, hyper-phosphorylation of Tau and cell death. The application of GSK-3 β fixes the disrupted cell signalling to restore cell functions	18
Figure 2.10	In normal condition, Wnt and SFRP will compete for binding on FRZ. The failure of Wnt to binds will cause the degradation of β -catenin mediated by GSK-3 β (a). The binding of Wnt will cause the dissociation of APC complex and the free β -catenin enters the nucleus and initiates the expression on cyclin-D1 and Myc to induce cell division and proliferation (b). However, the over accumulation of β -catenin and overexpression of cyclin D1 can lead to cancer (c)	19
Figure 2.11	The binding of GSK-3 inhibitor on GSK-3 on Asp133 and Val 135, which is a common characteristic shared by most GSK-3 inhibitors	20
Figure 2.12	The potential binding sites for the inhibition of GSK-3	21
Figure 2.13	The area of binding sites for GSK-3 inhibitor (Q185, D200 and R220 – red circle) and phosphate group from primed substrates (F67, 89-95 loop and P-binding pocket – blue circle). Overlapping binding sites cause competition between the inhibitor and primed substrate	22
Figure 2.14	ATP-competitive inhibitor will compete with phosphate group from primed substrate. Its attachment will prevent the binding of substrates and deactivate the activity of GSK-3	22
Figure 2.15	The structure of GSK-3 selective ATP-competitive inhibitors; 3-anilino-4-arylmaleimides (a), indolyl-maleimides (b), bis(indolyl)maleimide (c), staurosporine (d)	24
Figure 2.16	The interaction between GSK-3 selective ATP-competitive inhibitor on ATP-binding site of GSK-3. Each compound interacts with Gln185 (in blue circle). This binding influence the selectivity of these compounds against GSK-3, and also suggests that the structure of ATP-binding site of GSK-3 is slightly different compared with other kinases	25
Figure 2.17	The structure of non-selective ATP-competitive inhibitor of GSK-3; indirubin-3'-monoxime (a), BIO (b)	26

and 9-nitro-paullone (c)

- Figure 2.18 The binding of GSK-3 non-selective ATP-competitive inhibitors. These compounds are unable to form interaction with Gln185 (red circle), which cause poor selectivity 26
- Figure 2.19 The mode of inhibition in which the compounds will only inhibit the activity GSK-3 against pre-phosphorylated substrate (glycogen synthase). The GSK-3 is still able to phosphorylate the non-primed substrates (β -catenin). Thus, the inhibition of GSK-3 to cure diabetes would lead into the development of cancer cell from the excessive accumulation of β -catenin 27
- Figure 2.20 The structure and IC₅₀ values of non-ATP competitive inhibitors 28
- Figure 2.21 Common structural features between Ro31-8220 (a) and TDZD (b); 1,3-dicarbonyl moiety in a five-membered ring with a nitrogen atom between both carbonyl groups, which may contribute to compound interaction with GSK-3 β 29
- Figure 2.22 The binding of TDZD derivatives, a non-ATP competitive inhibitor (b) is suggested to bind with amino acids (R96, R180, K205) adjacent to tyrosine 216 (Y216). The ketone group TDZD (red circles) is forming hydrogen bonds with Arg96, Arg180 and Lys205. The molecule is proposed to be trapped and interacting with the hydrophobic pocket by Val214 and Tyr216 through hydrophobic and π -stacking (c). This will prevent the activation of GSK by phosphorylation at Tyr216 30
- Figure 2.23 The targeted pathway in yeast in which the expressed mammalian GSK-3 β will be part of Rog1 regulation pathway. GSK-3 β will dephosphorylate Rog1 to increase its affinity to form a complex with Bul1/Bul2 and Rsp5 and lead to degradation of Rog1 (a). In the presence of GK-3 β inhibitor, the Rog1 will cause the accumulation of Rog1 and lead to growth defects at 37 °C (b) 35
- Figure 2.24 The principle of Kinase-Glo Luminescence Kinase assay. Under normal reaction (a), the ATP will be converted into ADP as GSK-3 β mediates the transfer of γ -phosphate group to phosphorylate the substrate which will cause low RLU value. In the presence of 39

GSK-3 β inhibitor (b), the activity of GSK-3 β will be reduced and the free ATP will react with beetle luciferin, mediated by luciferase to produce oxyluciferin and light signal


Figure 2.25	Chemical structures of GSK-3 β inhibitors isolated from nature	41
Figure 2.26	Distribution of bioactive compounds discovered from actinomycetes	43
Figure 2.27	The structures of anticancer isolated from actinomycetes	46
Figure 2.28	The structure of GSK-3 β inhibitors isolated from <i>Streptomyces</i> sp. H7667 of rainforests of Sabah	47
Figure 4.1	The changes of color that can be observed as the purified strain is cultured in broth. The initial color of the mannitol-peptone broth is clear yellow (a) and after five days of incubation, most of the culture will develop a new color which indicates the release of secondary metabolites (b)	71
Figure 6.1	RP-HPLC profiles of F4 (a) and F8 (b); viewed at 210 nm	107
Figure 6.2	IR spectrum of F8	108
Figure 6.3	The GCMS chromatogram of F8 (active fraction from CC of H11809-Chloroform extract). A total of three compounds were identified; N-acetyltyramine (i), Cyclo-Leu-Pro (ii), Dibutyl Phthalates (iii)	109
Figure 6.4	The chromatogram of F8 before spiked (In blue) and after spiked with pure compounds (In orange) using commercial pure compounds	113
Figure 7.1	The plot that represents enzymatic reaction following Michaelis-Menten kinetics. V _{max} is the maximum velocity and K _m is the required substrate concentration to achieve half maximum velocity	117
Figure 7.2	The inhibitory activity of TDZD-8 (positive control), DKP and DBP (tested compounds) at 2 μ M for each compound against GSK-3 β	122
Figure 7.3	The RLU values produced with varies concentration of ATP and Cyclo-leu-pro	124

Figure 7.4	The plots to determine the changes of K_m and V_{max} values from inhibitory activity exerted by cyclo-leu-pro against GSK-3 β	125
Figure 7.5	The Lineweaver-Burke plot to visualize the inhibitory mechanisms caused by cyclo-leu-pro against GSK-3 β	126
Figure 7.6	Reaction scheme for full uncompetitive inhibition (a) and partial uncompetitive inhibition (b). E = enzyme, S = substrate, I = inhibitor, P = product	127
Figure 7.7	The RLU values at various concentrations of ATP and dibutyl phthalates	128
Figure 7.8	Michaelis-Menten plots to determine K_m and V_{max} values exerted by DBP at various concentrations against GSK-3 β	129
Figure 7.9	Lineweaver-Burke plot to visualize the inhibitory mechanisms caused by DBP against GSK-3 β	130
Figure 7.10	Reaction scheme for full mixed inhibition (a) and partial mixed inhibition (b). E = enzyme, S = substrate, I = inhibitor, P = product	131
Figure 7.11	The IC_{50} of cyclo-leu-pro. The calculation was performed using GraphPrism pad software	132
Figure 7.12	Plotted graph to determine the IC_{50} of dibutyl phthlate. The calculation was performed using GraphPrism pad software	133

LIST OF ABBREVIATION

1,3PG	1,3-Bisphosphoglycerate
2PG	2-Phosphoglycerate
3PG	3-Phosphoglycerate
ADP	Adenosine diphosphate
AIA	Actinomyces isolation agar
AKT	Protein kinase B
Ala	Alanine
ANNOVA	Analysis of variance
APCI	Atomic pressure chemical ionization
Arg	Arganine
Asn	Asparagine
Asp	Aspartic acid
ATP	Adenosine triphosphate
C18 column	Carbon 18 column
CALK	Aurora-like kinase
CBP	CREB-binding protein
CC	Column chromatography
CDKs	Cyclin-dependent kinase protein
ChCl3	Chloroform
CREB	cAMP response element-binding protein
DAP	L-diaminopimelic acid
DBH	Debromohymenialdisine
DBP	Dibutyl phthalates
DMSO	Dimethyl sulfoxide
EA	Ethyl acetate
EDTA	Ethylenediaminetetraacetic acid
EGTA	ethylene glycol tetraacetic acid
EI	Electron ionization
ESI	Electrospray ionization
F6P	Fructose-6-phosphate
FRAT1/2	requently rearranged in advanced T-cell lymphomas 1/2
FRZ	Frizzled
FT-IR	Fourier transform infrared spectroscopy
G6P	Glucose 6-phosphate
GAP	Glyceraldehyde 3-phosphate
GC-MS	Gas chromatography–mass spectrometry
Gln	Glutamine
Glu	Glutamic acid
GLUT4	Glucose transporters 4
GS	Glycogen synthase
GSK-3	Glycogen synthase kinase-3

HD	Hymendialdisine
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
Hex	Hexane
HIV	Human immunodeficiency virus
HMKs	Halomethylarylketones
HPLC	High-performance liquid chromatography
HVA	Humic acid agar + Vitamin B
ICL	Isocitrate lyase
Ile	Isoleucine
ISP3/4	International Streptomyces Project 3/4 agar
LC-MS	Liquid chromatography–mass spectrometry
Leu	Leucine
LLE	Liquid-liquid extraction
Lys	Lysine
MAPK	Mitogen-activated protein kinases
MAPs	microtubule-associated proteins
Met	Methionine
MKK1	Mitogen-activated protein kinase kinase 1
MSG5	Tyrosine protein phosphate 5
OA	Oatmeal agar
PBS	Phosphate buffer solutions
Phe	Phenylalanine
PKA/B/C	Protein kinase A/B/C
PP1	Protein phosphatase 1
PPT	Protein precipitation
Pro	Proline
Ser	Serine
SPE	Solid phase extraction
TDZDs	Thiadiazolidinones
Thr	Threonine
TLC	Thin layer chromatography
Tyr	Tyrosine
Val	Valine
VRE	Vancomycin resistant



LIST OF SYMBOLS

%	Percentage
[I]	Inhibitor concentration
[S]	Substrate concentration
µg	Microgram
µL	Microliter
µM	Micromolar
A	Absorbance
g	Gram
H₀	Null hypothesis
H₁	Alternative hypothesis
IC₅₀	Half-maximal inhibitory reaction
K_i	Inhibitory constant
K_m	Michaelis-Menten equation
M⁺	Molecular ion
m/z	Mass per charge
mg	Milligram
mg/mL	Milligram per milliliter
mL	Milliliter
mm	Millimeter
ng	Nanogram
OD	Optical density
°C	Degree Celsius
R_f	Retention value
RLU	Relative light unit
rpm	Revolutions per minute
v/v	Volume per volume
V_{max}	Maximum velocity
v₀	Velocity
α	Alpha
β	Beta



LIST OF APPENDICES

		Page
Appendix 1	Media and Ingredients	173
Appendix 2	Morphologies of isolated strains	179
Appendix 3	Interpretation of results from screenings	195
Appendix 4	Results of screening for GSK-3 β inhibitors	199
Appendix 5	Reagents for GSK-3 β assay	209
Appendix 6	Optimization of enzymatic assay	210
Appendix 7	Calculation for Michaelis-Menten plot	211



UMS
UNIVERSITI MALAYSIA SABAH

CHAPTER 1

INTRODUCTION

1.1 Introduction

Actinomycetes are gram positive bacteria commonly found in soil and sediment. They are regarded as the most promising source for new drugs due to their ability to produce active compounds with unique structural features and various biological activities (Takahashi and Omura, 2003; Toume *et al.*, 2014). For example, antimicrobial agents (streptomycin and erythromycin) (Schatz *et al.*, 2005; Shangavi *et al.*, 2014), anticancer agents (nonactin, tetracenomycin D, resistomycin and 1-hydroxy-1-norresistomycin) (Kock *et al.*, 2005; Jeong *et al.*, 2006) and antiparasitic agents (phenzamine 12 and Trioxacarcins) (Maskey *et al.*, 2004; Dashti *et al.*, 2014). Actinomycetes also gained interests to search for small molecule inhibitor targeting kinase proteins; especially glycogen synthase kinase-3 (GSK-3) (Ojo *et al.*, 2011).

GSK-3 is a serine/threonine kinase discovered in the 80's as a key regulator of glucose metabolism. It is expressed as two isoforms in human; GSK-3 α and GSK-3 β (97 % of similarities) which only differ on the length of their N-terminal (Woodgett, 1990). Extensive studies revealed that, GSK-3 involved in numerous signaling pathways and processes in human such as Wnt and Akt signalling, cell differentiation and cell survival (Jope and Johnson, 2004; Klann *et al.*, 2004; Grimes and Jope, 2011). Due to its diverse role in cells, its dysregulation may cause diseases such as cancer, neurodegenerative disease and diabetes; often due to overexpression of GSK-3 β (Elder-Finkelman *et al.*, 1999; Cohen and Goedert, 2004; Baylin and Ohm, 2006). Thus, molecule that can inhibit the activity of this enzyme is regarded as a potential curative way (Elder-Finkelman and Martinez, 2011). The example of GSK-3 β inhibitor which is clinically in used is lithium to treat neurodegenerative disease (Sun *et al.*, 2002). However, lithium is lack in specificity which raised concern that it might lead to other diseases such as cancer since it will